单孔经膀胱单纯前列腺切除术治疗良性前列腺增生:功能与控尿结局
本研究回顾性分析2020年2月至2024年3月连续89例接受经膀胱单孔机器人辅助单纯前列腺切除术(SP-RASP)的良性前列腺增生患者,中位前列腺体积110克,中位随访18个月。术后仅4例(4.5%)出现尿失禁,均在3个月内恢复控尿;末次评估中位IPSS 5分、QoL 1分、PVR 10 ml,77.5%患者同日出院,无Clavien-Dindo>2级并发症。
要点
- 经膀胱SP-RASP术后尿失禁发生率4.5%(4/89),均在3个月内恢复控尿。
- 末次随访中位IPSS 5分、QoL 1分、PVR 10 ml,功能结局改善。
- 77.5%患者同日出院,无Clavien-Dindo>2级并发症。
核心结论
- SP-RASP的尿失禁发生率和功能结局非常令人鼓舞,可能归因于精确的腺瘤和尿道分离以及膀胱颈重建;该入路也允许同日出院。
研究设计与样本
- 回顾性分析2020年2月至2024年3月连续接受经膀胱SP-RASP患者的临床与手术数据,数据来自前瞻性维护的机构数据集,共89例。
主要发现
- 中位前列腺体积110克(90-171.5),中位PSA 5.5 mg/dl(2.77-10.93),所有患者术前均使用至少一种前列腺药物。
- 术前中位IPSS 23(20-27)、QoL 4(3-5)、PVR 153 ml(60-400)。
- 中位手术时间180 min(164-200),中位估计出血量100 ml(30-180),术后无患者需要持续膀胱冲洗。
- 术后中位阿片类药物摄入6.5吗啡当量(0-10),超过78%患者出院后不需要麻醉性镇痛药;77.5%患者同日出院,无Clavien-Dindo>2级并发症记录。
- 中位随访18(7-35)个月,末次泌尿外科评估中位IPSS 5(3-7)、QoL 1(0-2)、PVR 10 ml(0-25);仅4例(4.5%)术后出现尿失禁,均在3个月内恢复控尿。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Robot-Assisted Simple Prostatectomy (RASP) is recommended for the treatment of large prostate glands. The introduction of the Single-Port (SP) platform in 2018 has enabled transvesical approach to SP-RASP with promising outcomes. Our aim was to describe the functional and urinary continence outcomes of SP-RASP. METHODS: Clinical and surgical data from all consecutive patients who underwent transvesical SP-RASP between February 2020 and March 2024 were collected in a prospectively maintained institutional dataset and retrospectively analyzed. All procedures were performed using the da Vinci SP platform without any conversions to open surgery. Postoperative outcomes were gathered and analyzed, with a particular focus on the incidence of urinary incontinence (UI) and the time to continence recovery. RESULTS: Overall, 89 patients underwent SP-RASP, with a median prostate size of 110 grams (90-171.5) and a median PSA level of 5.5 mg/dl (2.77-10.93). All patients were on at least one prostate medication prior to surgery. Preoperative evaluations showed a median International Prostate Symptoms Score (IPSS) of 23 (20-27), Quality of Life (QoL) of 4 (3-5), and Post-voiding Residual (PVR) of 153 ml (60-400). The median operative time was 180 min (164-200), with a median estimated blood loss of 100 ml (30-180). Postoperatively, no patients required continuous bladder irrigation. The median postoperative opioid intake was 6.5 morphine equivalents (0-10), with over 78% not requiring narcotics after discharge. Overall, 77.5% were same day discharged. No Clavien-Dindo > 2 complications were recorded. The median follow-up time was 18 (7-35) months. At the last postoperative urological evaluation, the median IPSS was 5 (3-7), QoL was 1 (0-2), and PVR was 10 ml (0-25). Only 4 patients (4.5%) experienced UI postoperatively, and all were continent within 3 months. CONCLUSIONS: The UI incidence rate and functional outcomes of SP-RASP are very encouraging, likely due to precise adenoma and urethra dissection and bladder neck reconstruction. This approach also allows for same-day discharge.
引用
- Pacini M, Lambertini L, Avesani G, et al. Single-port transvesical simple prostatectomy for the surgical treatment of benign prostatic hyperplasia: functional and continence outcomes. Prostate Cancer Prostatic Dis. 2024. PMID: 39562836. doi:10.1038/s41391-024-00923-y
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。